Lipocine Inc. cotiza a 1.66 USD y tiene una capitalización bursátil de $14M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an …
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.32 | $-0.54 | $-0.42 | $-0.59 |
| Estimado | $-0.40 | $-0.48 | $-0.61 | $-0.54 |
| Sorpresa | +20.0% | -12.5% | +31.1% | -9.3% |
| Métrica | LPCN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -524.7% | -38.6% | -486.1% |
| Net Margin | -487.1% | -33.6% | -453.5% |
| FCF Margin | — | -13.9% | — |
| ROE | -66.5% | -40.4% | -26.1% |
| ROA | -56.6% | -32.0% | -24.6% |
| Current Ratio | 6.68 | 2.84 | +3.84 |
| Debt / Equity | — | 0.28 | — |